199 related articles for article (PubMed ID: 22167612)
21. Update on the management of lupus nephritis: let the treatment fit the patient.
Bertsias G; Boumpas DT
Nat Clin Pract Rheumatol; 2008 Sep; 4(9):464-72. PubMed ID: 18756272
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies.
Schiavo AL; Puca RV; Ruocco V; Ruocco E
Clin Dermatol; 2010; 28(3):337-43. PubMed ID: 20541689
[TBL] [Abstract][Full Text] [Related]
23. Myasthenia gravis: emerging new therapy options.
Sieb JP
Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
[TBL] [Abstract][Full Text] [Related]
24. Induction and maintenance therapy in proliferative lupus nephritis.
Ponticelli C; Glassock RJ; Moroni G
J Nephrol; 2010; 23(1):9-16. PubMed ID: 20091481
[TBL] [Abstract][Full Text] [Related]
25. [Allergo-immunology. Clinical immunology].
Chizzolini C
Rev Med Suisse; 2012 Jan; 8(323):11-3. PubMed ID: 22303732
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.
Rabasco C; Cavero T; Román E; Rojas-Rivera J; Olea T; Espinosa M; Cabello V; Fernández-Juarez G; González F; Ávila A; Baltar JM; Díaz M; Alegre R; Elías S; Antón M; Frutos MA; Pobes A; Blasco M; Martín F; Bernis C; Macías M; Barroso S; de Lorenzo A; Ariceta G; López-Mendoza M; Rivas B; López-Revuelta K; Campistol JM; Mendizábal S; de Córdoba SR; Praga M;
Kidney Int; 2015 Nov; 88(5):1153-60. PubMed ID: 26221755
[TBL] [Abstract][Full Text] [Related]
27. Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011).
Wang A; Smith JR; Creevy KE
J Small Anim Pract; 2013 Aug; 54(8):399-404. PubMed ID: 23879827
[TBL] [Abstract][Full Text] [Related]
28. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.
Sinha A; Gulati A; Saini S; Blanc C; Gupta A; Gurjar BS; Saini H; Kotresh ST; Ali U; Bhatia D; Ohri A; Kumar M; Agarwal I; Gulati S; Anand K; Vijayakumar M; Sinha R; Sethi S; Salmona M; George A; Bal V; Singh G; Dinda AK; Hari P; Rath S; Dragon-Durey MA; Bagga A;
Kidney Int; 2014 May; 85(5):1151-60. PubMed ID: 24088957
[TBL] [Abstract][Full Text] [Related]
29. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
30. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.
Boletis JN; Marinaki S; Skalioti C; Lionaki SS; Iniotaki A; Sfikakis PP
Nephrol Dial Transplant; 2009 Jul; 24(7):2157-60. PubMed ID: 19179411
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapies in neurologic disorders.
Graves D; Vernino S
Med Clin North Am; 2012 May; 96(3):497-523, x. PubMed ID: 22703853
[TBL] [Abstract][Full Text] [Related]
32. New treatment strategies for proliferative lupus nephritis: keep children in mind!
Ranchin B; Fargue S
Lupus; 2007; 16(8):684-91. PubMed ID: 17711908
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in primary membranous nephropathy: first-line therapy, why not?
Cravedi P; Remuzzi G; Ruggenenti P
Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
[TBL] [Abstract][Full Text] [Related]
34. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen.
Tedeschi B; Arnaud L; Hie M; Mathian A; Amoura Z
Ann Rheum Dis; 2014 Feb; 73(2):474-5. PubMed ID: 24001887
[No Abstract] [Full Text] [Related]
36. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
37. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
Zand L; Specks U; Sethi S; Fervenza FC
Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
[TBL] [Abstract][Full Text] [Related]
38. Current and prospective pharmacotherapy for autoimmune hepatitis.
Czaja AJ
Expert Opin Pharmacother; 2014 Aug; 15(12):1715-36. PubMed ID: 24961409
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
[TBL] [Abstract][Full Text] [Related]
40. Maintaining remission in a patient with vasculitis.
Flossmann O; Jayne DR
Nat Clin Pract Rheumatol; 2008 Sep; 4(9):499-504. PubMed ID: 18648340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
